-
2023-507781-13-00
1
2024-05-24
Patients with relapsed/refractory acute myeloid leukemia or myelodyspl
-
2023-506881-30-00
3
2024-05-15
Melanoma
-
2023-507321-42-00
1
2024-02-15
Myelodysplastic syndrome (MDS)
-
2023-505543-39-00
5
2024-02-12
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-507304-32-00
6
2024-02-09
Chronic Obstructive Pulmonary Disease
-
2023-505910-10-00
4
2024-01-23
Relapsed or Refractory High-Risk Myelodysplastic Syndrome
-
2023-503627-26-00
4
2023-09-28
Metastatic breast cancer
-
2022-502620-49-00
2
2023-08-01
Resected Melanoma Stage III or Stage IV
-
2022-501601-12-00
4
2023-05-22
Diffuse large B-cell Lymphoma
-
2024-515744-23-00
1
2023-02-15
Relapsed or refractory (R/R) Acute lymphoblastic leukemia (ALL), R/R A
-
2023-504238-23-00
5
2023-01-17
Hepatitis B, Chronic
-
2023-503529-20-00
4
2022-10-17
BRCA Mutations and Early Stage HER2-Negative Breast Cancer
-
2024-513993-23-00
9
2022-09-21
Patients with higher risk myelodysplastic syndrome (MDS) who have not
-
2024-514372-40-00
5
2022-04-12
Anterior ST-Elevation Myocardial Infarction
-
2023-508828-35-01
5
2022-03-28
Patients with advanced hormone receptor-positive/HER2- negative/HER2-E
-
2023-507093-40-00
4
2022-01-27
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-514611-98-00
5
2021-07-20
PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previousl
-
2024-512012-21-00
5
2021-04-08
Chronic Obstructive Pulmonary Disease
-
2022-502244-12-00
5
2021-02-22
Metastatic hormone-sensitive prostate cancer (mHSPC)
-
2024-511295-33-00
4
2020-08-13
Study to evaluate the effect of metformin in the prevention of hypergl
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2023-507498-16-00
9
2019-07-02
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-501970-20-01
5
2019-06-07
Cis-eligible Muscle-invasive bladder cancer.
-
2023-508655-39-00
7
2019-02-13
Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)